Procter & Gamble Company: Indivior Appoints Vanessa Procter to Enhance Opioid Treatment Commitment
- Indivior PLC appoints Vanessa Procter as Executive Vice President of Corporate Affairs to enhance treatment accessibility for opioid use disorder.
- Procter brings over 25 years of experience in pharmaceutical policy, advocating for improved public health initiatives at Indivior.
- Indivior aims to reframe opioid use disorder as a chronic disease, focusing on evidence-based treatments and patient awareness.
Indivior PLC Strengthens Commitment to Opioid Use Disorder Treatment with New Executive Appointment
Indivior PLC, a leading pharmaceutical company dedicated to the treatment of opioid use disorder (OUD), announces the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. With over 25 years of experience in the biopharmaceutical sector, Procter will play a pivotal role in overseeing Corporate Communications, Government Affairs, Policy, and Advocacy. CEO Joe Ciaffoni welcomes Procter's expertise, highlighting her track record in aligning diverse teams and executing strategic initiatives that enhance patient access within complex regulatory landscapes.
Procter's prior experience includes serving as Senior Vice President of Corporate Affairs at Sage Therapeutics, where she significantly contributed to the launch of ZURZUVAE™, the first oral medication for postpartum depression. Her extensive career also encompasses leadership roles in corporate and government affairs at major firms such as Alexion Pharmaceuticals and MedImmune. Additionally, Procter brings a unique perspective from her time as a health policy advisor in the U.S. House of Representatives, enabling her to navigate the intersection of healthcare policy and pharmaceutical development effectively. This background positions her well to advocate for OUD treatment and drive public health initiatives at Indivior.
As Indivior expands its portfolio and product pipeline, Procter emphasizes her commitment to addressing public health challenges through active policy engagement and community involvement. The company remains dedicated to reframing OUD as a chronic disease, advocating for improved treatment accessibility for patients worldwide. With Procter's leadership, Indivior aims to enhance its efforts in providing evidence-based treatments and raising awareness about the complexities of OUD, reinforcing its mission to transform the lives of those affected by this global crisis.
In related news, the focus on public health and regulatory affairs continues to be a significant theme within the pharmaceutical industry. Indivior's strategic appointments and initiatives reflect a broader trend where companies prioritize experienced leadership to navigate the evolving landscape of healthcare regulations and patient access. As the opioid crisis persists, companies like Indivior are well-positioned to lead efforts in transforming treatment paradigms and improving outcomes for individuals struggling with OUD.
The appointment of Vanessa Procter marks a critical step for Indivior in its mission to enhance treatment accessibility and tackle the pressing issues surrounding opioid addiction. By leveraging her extensive background in policy and advocacy, Procter is set to elevate the company's influence in the biopharmaceutical sector and drive meaningful change in the lives of patients.